Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first‐line treatment within the randomized Phase III trial FIRE ‐3 ( AIO KRK ‐0306)-Reference-Cited by-同舟云学术

Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first‐line treatment within the randomized Phase III trial FIRE ‐3 ( AIO KRK ‐0306)

Published:2021-09-06 Issue:1 Volume:150 Page:112-123
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Liu Lian¹,Erickson Nicole Tonya¹,Ricard Ingrid¹,Weikersthal Ludwig Fischer²,Lerch Markus M.³,Decker Thomas⁴,Kiani Alexander⁵,Kaiser Florian⁶⁷,Heintges Tobias⁸,Kahl Christoph⁹,Kullmann Frank¹⁰,Scheithauer Werner¹¹,Link Hartmut¹²,Höffkes Heinz‐Gert¹³,Moehler Markus¹⁴,Gesenhues Alena Britta¹⁵,Theurich Sebastian¹⁶¹⁷¹⁸,Michl Marlies¹¹⁶,Modest Dominik P.¹¹⁶¹⁸¹⁹,Algül Hana²⁰,Stintzing Sebastian¹⁸¹⁹,Heinemann Volker¹¹⁶¹⁸,Holch Julian W.¹¹⁶¹⁸

Affiliation:

1. Comprehensive Cancer Center University Hospital, LMU Munich Munich Germany

2. Gesundheitszentrum St Marien Amberg Germany

3. Klinik und Poliklinik für Innere Medizin A, Universitätsmedizin Greifswald Greifswald Germany

4. Studienzentrum Onkologie Ravensburg Ravensburg Germany

5. Klinikum Bayreuth GmbH Bayreuth Germany

6. Praxis Hämatologie/Onkologie/Palliativmedizin—Tagesklinik Landshut Germany

7. VK&K Studien GbR Landshut Germany

8. Lukaskrankenhaus Neuss Neuss Germany

9. Städtisches Klinikum Magdeburg, Hämatologie/ Onkologie Magdeburg Germany

10. Klinikum Weiden, Medizinische Klinik I Weiden Germany

11. Department of Internal Medicine I and Comprehensive Cancer Center Medical University of Vienna Vienna Austria

12. Department of Medicine I Westpfalz‐Klinikum GmbH Kaiserslautern Germany

13. Klinikum Fulda, Tumorklinik Fulda Germany

14. Medical Department 1 Johannes‐Gutenberg Universität Mainz Mainz Germany

15. Department of Radiology University Hospital, LMU Munich Munich Germany

16. Department of Medicine III University Hospital, LMU Munich Munich Germany

17. Cancer‐ and Immunometabolism Research Group, Gene Center LMU Munich Munich Germany

18. German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ) Heidelberg Germany

19. Department of Hematology, Oncology, and Tumorimmunology Charité – Universitaetsmedizin Berlin Germany

20. Comprehensive Cancer Center Munich TUM, Klinikum rechts der Isar, Technische Universität München Munich Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33775

Reference40 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Cancer treatment and survivorship statistics, 2014

3. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

4. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

5. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations between Patient-Generated Subjective Global Assessment criteria and all-cause mortality among cancer patients: Evidence from baseline and longitudinal analyses;Nutrition;2024-11

2. The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review;Journal of Cachexia, Sarcopenia and Muscle;2024-08-02

3. Post‐diagnosis adiposity and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis;International Journal of Cancer;2024-05

4. Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies;ESMO Open;2024-03

5. Therapeutic potential of mangiferin in cancer: Unveiling regulatory pathways, mechanisms of action, and bioavailability enhancements – An updated review;Food Science & Nutrition;2023-12-20